Wiesweg M, Preuss C, Roeper J, Metzenmacher M, et al. BRAF mutations and BRAF mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapy. Eur J Cancer 2021;149:211-221.
PMID: 33872981